FNDC5 and pulmonary arterial hypertension: In addition, plasma irisin levels are significantly reduced in patients with PAH compared with that in the control group (Figure 1D), and patients with high‐risk stratification presented with even lower plasma irisin levels (Figure 1I), indicating the potential of irisin as a useful biomarker for PAH risk stratification.